ZON Platform
Undisclosed (Anti-pathogen, potential genetic disorders)
Research/Pre-clinicalActive
Key Facts
Indication
Undisclosed (Anti-pathogen, potential genetic disorders)
Phase
Research/Pre-clinical
Status
Active
Company
About Zata Pharmaceuticals
Zata Pharmaceuticals is a preclinical-stage biotech leveraging the foundational work of co-founder Dr. Paul Zamecnik, a pioneer in antisense therapy. Its core assets include GLS409, a dual-target antiplatelet candidate for sublingual emergency use, and its proprietary ZON oligonucleotide platform. The company is pre-revenue, operates with a lean team, and has established key academic partnerships while recently monetizing one asset (ZAP-Systems) through an acquisition.
View full company profile